Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Cash from Investing Activities: 2013-2025

Historic Cash from Investing Activities for Coherus Oncology (CHRS) over the last 12 years, with Sep 2025 value amounting to -$67.2 million.

  • Coherus Oncology's Cash from Investing Activities fell 15241.22% to -$67.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $377.4 million, marking a year-over-year increase of 41.84%. This contributed to the annual value of $230.3 million for FY2024, which is 59.24% up from last year.
  • Per Coherus Oncology's latest filing, its Cash from Investing Activities stood at -$67.2 million for Q3 2025, which was down 114.53% from $462.6 million recorded in Q2 2025.
  • Coherus Oncology's 5-year Cash from Investing Activities high stood at $462.6 million for Q2 2025, and its period low was -$285.5 million during Q1 2021.
  • Moreover, its 3-year median value for Cash from Investing Activities was $27.7 million (2024), whereas its average is $68.4 million.
  • In the last 5 years, Coherus Oncology's Cash from Investing Activities plummeted by 17,565.53% in 2021 and then skyrocketed by 11,160.39% in 2023.
  • Over the past 5 years, Coherus Oncology's Cash from Investing Activities (Quarterly) stood at $107.5 million in 2021, then crashed by 220.85% to -$129.9 million in 2022, then soared by 127.10% to $35.2 million in 2023, then crashed by 101.54% to -$542,000 in 2024, then crashed by 15,241.22% to -$67.2 million in 2025.
  • Its Cash from Investing Activities stands at -$67.2 million for Q3 2025, versus $462.6 million for Q2 2025 and -$17.5 million for Q1 2025.